Cancer-targeted oncolytic adenoviruses for modulation of the immune system.

Related Articles

Cancer-targeted oncolytic adenoviruses for modulation of the immune system.

Curr Cancer Drug Targets. 2017 May 02;:

Authors: Cerullo V, Capasso C, Vähä-Koskela M, Hemminki O, Hemminki A

Abstract
Adenovirus is one of the most commonly used vectors for gene therapy and it is the first approved virus-derived drug for treatment of cancer. As an oncolytic agent, it can induce lysis of infected cells, but it can also engage the immune system, promoting activation and maturation of antigen-presenting cells (APCs). In essence, oncolysis combined with the associated immunostimulatory actions result in a "personalized in situ vaccine" for each patient. In order to take full advantage of these features, we should try to understand how adenovirus interacts with the immune system, what are the receptors involved in triggering subsequent signals and which kind of responses they elicit. Tackling these questions will give us further insight in how to manipulate adenovirus-mediated immune responses for enhancement of anti-tumor efficacy. In this review, we first highlight how oncolytic adenovirus interacts with the innate immune system and its receptors such as Toll-like receptors, nucleotide-binding and oligomerization domain (NOD)-like receptors and other immune sensors. Then we describe the effect of these interactions on the adaptive immune system and its cells, especially B and T lymphocytes. Finally, we summarize the most significant preclinical and clinical results in the field of gene therapy where researchers have engineered adenovirus to manipulate the host immune system by expressing cytokines and signaling mediators.

PMID: 28464762 [PubMed - as supplied by publisher]

from Cancer via ola Kala on Inoreader http://ift.tt/2pBwsNj
via IFTTT